MarketCap
Perrigo Company plc PRGO
$ 13.04
1.64%
Facebook
X
Telegram
Perrigo Company plc Book Value | PRGO
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Perrigo Company plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.94 B | 4.32 B | 4.77 B | 4.84 B | 5.15 B | 5.66 B | 5.8 B | 5.67 B | 6.17 B | 5.96 B | 10.7 B | 8.69 B | 2.33 B | 1.85 B | 1.53 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.7 B | 1.53 B | 5.09 B |
Quarterly Book Value Perrigo Company plc
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.52 B | 2.5 B | 4.45 B | 4.47 B | 4.36 B | 4.32 B | 4.57 B | 4.55 B | 4.69 B | 4.77 B | 4.74 B | 4.85 B | 4.83 B | 4.84 B | 4.6 B | 4.85 B | 5.1 B | 5.15 B | 5.18 B | 5.51 B | 5.56 B | 5.66 B | 5.66 B | 5.66 B | 5.66 B | 5.8 B | 5.8 B | 5.8 B | 5.8 B | 5.67 B | 5.67 B | 5.67 B | 5.67 B | 6.17 B | 6.17 B | 6.17 B | 6.17 B | 5.96 B | 5.96 B | 5.96 B | 5.96 B | 10.1 B | 10.1 B | 10.1 B | 10.1 B | 9.72 B | 8.72 B | 8.72 B | 8.72 B | 13.7 B | 5.51 B | 10.7 B | 13.1 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 13.7 B | 13.1 M | 6.03 B |
Book Value of other stocks in the Drug manufacturers industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ProPhase Labs
PRPH
|
3.51 M | - | - | $ 5.07 M |  USA |
 |
Aurora Cannabis
ACB
|
609 M | $ 3.68 | 0.13 % | $ 202 M |  Canada |
 |
Cronos Group
CRON
|
1.14 B | $ 3.14 | 0.07 % | $ 1.2 B | Canada |
 |
Evoke Pharma
EVOK
|
7.04 M | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
314 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.86 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
17 M | - | 7.5 % | $ 6.35 M | USA |
 |
Evolus
EOLS
|
-23.1 M | $ 8.15 | 1.68 % | $ 525 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-651 K | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
24.5 M | $ 7.79 | 0.27 % | $ 116 M | USA |
 |
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | - | - | $ 2.06 B |  France |
 |
Athenex
ATNX
|
-24.2 M | - | -23.39 % | $ 1.76 M | USA |
 |
Catalent
CTLT
|
3.6 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
18.3 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Jupiter Wellness
JUPW
|
35 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | USA |
 |
Harrow Health
HROW
|
52.1 M | $ 40.03 | 2.98 % | $ 1.47 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
265 M | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
94 M | - | - | $ 150 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
46.2 M | - | - | $ 55.5 M | USA |
 |
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-40.4 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
51.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Zomedica Corp.
ZOM
|
115 M | - | -0.21 % | $ 98 M | USA |
 |
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | USA |
 |
Bausch Health Companies
BHC
|
377 M | $ 6.51 | 2.6 % | $ 2.41 B | Canada |
 |
Emergent BioSolutions
EBS
|
523 M | $ 4.59 | 2.34 % | $ 246 M | USA |
 |
China Pharma Holdings
CPHI
|
22.7 M | $ 1.13 | 3.67 % | $ 4.85 M |  China |
 |
OrganiGram Holdings
OGI
|
306 M | $ 1.23 | 0.78 % | $ 117 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
3.1 M | $ 1.3 | 0.75 % | $ 2.19 M | USA |
 |
SCYNEXIS
SCYX
|
49.4 M | $ 5.18 | 1.17 % | $ 259 M | USA |
 |
TherapeuticsMD
TXMD
|
26.9 M | $ 2.07 | 0.38 % | $ 23.9 M | USA |
 |
Solid Biosciences
SLDB
|
180 M | $ 9.2 | 1.32 % | $ 805 M | USA |
 |
Veru
VERU
|
18.3 M | $ 2.73 | 1.11 % | $ 40 M | USA |
 |
cbdMD
YCBD
|
7.23 M | $ 0.49 | 5.19 % | $ 1.97 M | USA |
 |
Canopy Growth Corporation
CGC
|
698 M | $ 1.02 | 0.99 % | $ 304 M | Canada |
 |
Rockwell Medical
RMTI
|
37 M | $ 7.41 | 4.19 % | $ 267 M | USA |
 |
Relmada Therapeutics
RLMD
|
86.5 M | $ 4.8 | 1.05 % | $ 190 M | USA |
 |
Organogenesis Holdings
ORGO
|
434 M | $ 1.79 | 1.7 % | $ 227 M | USA |
 |
Pacira BioSciences
PCRX
|
693 M | $ 23.0 | 0.04 % | $ 1.03 B | USA |
 |
Sundial Growers
SNDL
|
1.1 B | $ 1.26 | 0.8 % | $ 325 M | Canada |
 |
Tilray
TLRY
|
1.49 B | $ 4.67 | 0.43 % | $ 4.16 B | Canada |